{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 101 of 128', 'SAEs will be evaluated separately and a narrative for each will be given.', 'Adverse events of special interest will be tabulated by treatment group.', 'AEs leading to withdrawal from trial and AEs leading to permanent discontinuation of IMP', 'will be tabulated by treatment group.', '14.3.9.2 Vital signs', 'The change in vital signs (blood pressure, pulse, body temperature) from baseline to each visit', 'will be summarised as mean, standard deviation, median, minimum, and maximum values for', 'each treatment group.', '14.3.9.3 Clinical laboratory evaluation', 'The change in each of the laboratory parameters from baseline to each visit will be', 'summarised by visit and treatment group as mean, standard deviation, median, minimum, and', 'maximum values.', 'Laboratory parameters will be classified as \"low\\', \\'normal\\' or \"high\\', depending on whether', 'the value is below, within or above the reference range, respectively. A shift table will be', 'produced showing the categories at baseline against those at end of treatment. Subjects with', 'laboratory parameters outside the reference range will be listed.', '14.3.9.4 Subject assessment of local tolerability', 'Subject assessment of local tolerability will be summarised by visit and treatment group.', '14.3.10', 'Pharmacokinetics', 'A separate report will be written by the respective bioanalytical CRO and added as an', 'addendum to the CTR.', 'Plasma concentrations of delgocitinib will be listed and plotted versus time since last IMP', 'application by treatment group.', '14.3.11', 'Interim analysis', 'No interim analysis is planned.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 102 of 128', '14.3.12', 'General principles', 'Unless otherwise stated, all significance tests will be 2-sided using the 5% significance level.', 'All CIs will be presented with 95% degree of confidence.', 'An observed-cases approach will be used for tabulations of data by visit (i.e., involving only', 'those subjects who attended each specific visit).', 'Categorical data will be summarised using the number and percentage of subjects in each', 'category and treatment group. Continuous data will be summarised using the mean, median,', 'standard deviation, minimum, and maximum values.', 'All the analyses specified in the protocol will be reviewed in relation to the blinded data', 'actually obtained and the statistical analysis plan will be finalised before breaking the', 'randomisation code.', 'Any changes from the statistical analysis planned in this clinical trial protocol will be', 'described and justified in a protocol amendment, the statistical analysis plan and/or in the', 'CTR dependent on the type of deviation.', '14.3.13', 'Handling of missing values', 'Procedures for handling of missing values are included under the sections describing the', 'individual analyses.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 103 of 128', '15 References', '1. Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al.', 'Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol', 'Ges. 2015; 13(1): el-e22.', '2.', 'Habif TP. Clinical dermatology: a color guide to diagnosis and therapy (5th edition). New', 'York: Mosby. 2010.', '3. Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Sheng Duh M.', 'Impact of chronic hand dermatitis on quality of life, work productivity, activity', 'impairment, and medical costs. J Am Acad Dermatol. 2006; 54: 448-57.', '4. Lerbaek A, Kyvik KO, Ravn H, Menn\u00e9 T, Agner T. Clinical characteristics and', 'consequences of hand eczema - an 8-year follow-up study of a population-based twin', 'cohort. Contact Dermatitis. 2008; 58: 210-216.', '5. Cvetkovski RS, Rothmann KJ, Olsen J, Mathiesen B, Iversen L, Johansen JD, Agner T.', 'Relation between diagnoses on severity, sick leave and loss of job among patients with', 'occupational hand eczema. B J Dermatol. 2005; 152: 93-98.', '6. Belsito DV, Fowler JF, Marks JG, Pariser DM, Hanifin J, Duarte IAG, Pires MC, Cruz', 'PD, Langley RGB, Patel P, Bush C, Thurston M, Graeber M, Cherill R and the', 'Multicenter Group. Pimecrolimus cream 1%: A potential new treatment for chronic hand', 'dermatitis. Cutis. 2004; 73: 31-38.', '7. Hordinsky M, Fleischer A, Rivers JK, Poulin Y, Belsito D, Hultsch T. Efficacy and safety', 'of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: A randomized,', 'double-blind trial. Dermatology. 2010; 221: 71-77.', \"8. Pesu M, Candotti F, Husa M, Hofmann SR, Notaraangelo LD, O'Shea JJ. Jak3, severe\", 'combined immunodeficiency, and a new class of immunosuppressive drugs. Immunolog', 'Rev. 2005;203:127-142.', '9. Murray PJ. The JAK-STAT signalling pathways: input and output integration. Journal of', 'Immunology. 2007;178:2623-2629.', '10. Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase', 'inhibitor JTE-052 improves skin barrier function through suppressing signal transducer', 'and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136:667-77.']\n\n###\n\n", "completion": "END"}